drugset / Trial / NCT05988216
Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus
Recruiting
12 enrolled
Bioray Laboratories
First Affiliated Hospital of Zhejiang University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the refractory systemic lupus erythematosus.
Timeline
- Start
- 2023-08-14
- Primary completion
- 2024-12
- Completion
- 2025-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BRL-301 | Cell therapy | — | — |